Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

  1. Colleen GC McGregor
  2. Alex Adams
  3. Ross Sadler
  4. Carolina V Arancibia-Cárcamo
  5. Rebecca Palmer
  6. Tim Ambrose
  7. Oliver Brain
  8. Alissa Walsh
  9. Paul Klenerman
  10. Simon PL Travis
  11. Nicholas M Croft
  12. James O Lindsay
  13. Jack Satsangi

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1136/gutjnl-2021-324116
  2. ScreenIT

    SciScore for 10.1101/2020.12.12.20247841: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    SARS-CoV-2 antibody detection: Sera from all patients were tested using the Abbott SARS-CoV-2 IgG assay and Architect i2000SR system, by staff in Oxford.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    We recognise limitations of our study; including limited power, incomplete exposure history and the presence of confounders with control data comparisons. Whilst the impact of shielding and social distancing practices observed by patients must be considered when interpreting these seroprevalence rates, we consider these findings to be informative, providing evidence to support the continuation of biologics in the COVID-19 era, especially considering the emerging data of deleterious IBD outcomes in those who have discontinued IBD medications during the pandemic(8). We cannot comment on the durability of response with a single timepoint or whether seropositive patients are protected from re-infection, and therefore we highlight the need for larger, multicentre, prospective, longitudinal studies such as the ICARUS and CLARITY studies, in order to answer the questions of durability and strength of serological response, immunomodulation on SARS-CoV-2 course and risk stratification. These studies also have potential implications in the prioritisation of vaccine delivery in IBD cohorts.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.12.12.20247841v2 on medRxiv
  4. Version published to 10.1101/2020.12.12.20247841v1 on medRxiv